Blogger's Note: interesting study worth reading
Background
Conclusions
IOERT may be feasible and effective as a boosting technique for advanced and recurrent ovarian cancer. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low risk of toxicity. Peripheral nerves in the IOERT field are dose-limiting structures requiring nerve protection policies or a dose compromise to ensure against severe neurological damage.
Patients
This study was a non-randomized trial and included retrospective analysis of 45 women with EOC who were treated with IOERT at the 1st Affiliated Hospital of the Medical College of Xi'an Jiaotong University between January 2000 and January 2010.........The mean follow-up time was 78 months (range: 11-123 months).........
Table 1
Patient Characteristics
| Total | PD | ILR | |
|---|---|---|---|
| Cases | 45 | 25 | 20 |
| Histology type | |||
| serous adenocarcinoma | 36 | 21 | 16 |
| papillary adenocarcinoma | 9 | 4 | 4 |
| CA-125 level | |||
| ≥ 35 U/ml | 38 | 20 | 18 |
| < 35 U/ml | 4 | 3 | 1 |
| unknown | 3 | 2 | 1 |
Conclusions
IOERT may be feasible and effective as a boosting technique to treat advanced and recurrent ovarian cancers. IOERT plus IP chemotherapy may achieve high locoregional disease control and survival benefit with a low risk of toxicity. However, careful attention should be paid to peripheral nerves as specific IOERT dose-limiting structures.
